Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
An estimated 21 million American women experience BV
The plant is scheduled to come on stream in September 2024
No new studies have been requested
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
It paves the way for an industry Code of Good Practice
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Subscribe To Our Newsletter & Stay Updated
